For reference: SSA · survodutide.
Something has gone wrong and I would like to know how badly before I decide what to do.
Nothing else in the setup changed, which is what makes this puzzling.
What would you check first, and what would you conclude from each outcome?
The practical consequence is that spot-testing one vial from a new supplier is better than assuming they are all the same.
The statistical foundation here is well-established, which is why sampling plans from decades ago are still valid.
| Δ mass (Da) | Most likely cause | Distinguishing feature |
|---|---|---|
| +1 | Deamidation (Asn or Gln) | New peak, slightly earlier retention |
| −17 | Loss of ammonia | Often with deamidation |
| −18 | Dehydration / succinimide | pH-dependent, reversible |
| +16 | Oxidation (Met, Trp) | Earlier retention, light-related |
| −128 | Missing Gln or Lys | Deletion sequence from synthesis |
| 0 | Isomer: racemisation or scrambling | Same mass, shifted retention |
For a quantitative result like content, the acceptable range determines how many vials you need to test to establish the lot complies.
Sampling plans for pharmaceutical manufacturing are defined in ISO 2859 and ANSI Z1.4, and they are based on statistical sampling theory.
I would treat a "complies with" statement without sampling details as a claim rather than as evidence.
The practical summary: a lot number without a sampling statement is a lot number without meaning.
Aggregated, published test results and vendor ratings built from submitted batches. Methodology stated, dataset browsable, no listing fees.
Browse resultsThermal history during shipping is different for every vial, so a lot that experienced thermal abuse may have internal variation even if it was originally homogeneous.
Stratified sampling — testing one vial from the top, one from the middle, and one from the bottom of a shipment — is cheap insurance against segregation.
If you have reason to suspect inhomogeneity — different appearance in different vials, or a long or warm shipment — testing more vials is the diagnostic move.
Published data on lot homogeneity from manufacturers who sample multiple vials consistently find variation below the published specifications, suggesting the sampling plans work.
One qualification: testing more vials gives better confidence, but at some point the cost outweighs the benefit.
If testing multiple vials, state how many you tested and why you chose those vials.
Concretely, sampling plans exist precisely because testing everything is expensive, and they define the statistical relationship between sample size and lot-wide inference.
Published segregation failures show that even modern automated processes sometimes produce lots with measurable vial-to-vial variation.
More usefully, testing a vial that has been open in the lab for three months is testing aged material, not the fresh lot, and the result should be explicitly noted as a retest.
Assume segregation is possible, and design your sampling to catch it if it exists.
edited 11 Oct 2025 by j_wierzbicki — tightened the wording; no substantive change
More usefully, the failure mode here is publishing a result that applies to the tested vial alone while implying it applies to the entire lot.
The sample size determination requires choosing a confidence level and an acceptable error rate, and the smaller the error rate you want, the larger your sample must be.
Lyophilised peptide homogeneity studies show that vial-to-vial variation is usually small but occasionally large, depending on the distribution in the freeze-dryer.
If you only pay for one test, pay for quantified content. Purity is the number everyone quotes and content is the number that changes what you do.
The honest statement is that unless you have tested multiple vials or have segregation data, you are making an assumption about lot homogeneity that may not hold.
If the lot was manufactured in multiple batches, testing vials from each batch separately establishes whether batch-to-batch variation is acceptable.
The ICH Q3A and Q3B thresholds for reporting, identification and qualification of impurities are the framework the pharmaceutical industry works to, and they are worth reading even though nothing in the research-grade supply chain is obliged to meet them, because they tell you which numbers a competent analyst would consider worth reporting at all.
In practice: ask for the chromatogram, check the method section, check the lot number against the vial, and set your accept threshold before you see the result rather than after.
Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.